BioCardia, Inc.
corporate_fare Company Profile
BioCardia, Inc. (NASDAQ:BCDA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for BCDA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for BCDA spans 8-K, 10-Q, 4.
Recent high-impact activity:
- BioCardia Hit With Nasdaq Notice Over $835K Stockholders' Equity vs $2.5M Minimum
- BioCardia Q3: $2.2M Cash, Going Concern Doubt Beyond January 2027, ATM Exhausted
- FDA Says Ongoing CardiAMP HF II Trial May Support Approval
- FDA Finalizes Helix Catheter Meeting Minutes; BioCardia to Submit Follow-On Pre-Submission This Quarter
- BioCardia Receives Nasdaq Minimum Bid Price Deficiency Notice
Financial Snapshot
Short Interest & Short Volume
6.29 days to coverFINRA reported short interest of 735,104 shares in BCDA as of the October 30, 2026 settlement, a 8.4% increase from the prior period — about 6.3 days to cover at its recent average daily volume. On November 20, 2026, 66.9% of BCDA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for BCDA, detected from its recent SEC filings · based on capital-structure filings through 2026-08-12.
Cash Runway Extended · ATM Program Exhausted
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →